Tempus Labs: Inside the $100M Data Boom—How Licensing Deals Are Reshaping Its Future!

Tempus AI’s third-quarter financial performance in 2025 presented a mixed picture with several encouraging elements coupled with areas of potential concern or uncertainty. The company demonstrated robust growth in its genomic and data licensing businesses, achieving a significant milestone of positive adjusted EBITDA for the first time in its history. In particular, Tempus AI reported a 33% increase in overall genomic volume, with oncology and hereditary tests growing at 27% and 37%, respectively. The hereditary segment exceeded expectations and is anticipated to continue growing, albeit at a slightly moderated rate. Tempus anticipates further growth in its genomics business with the MRD (minimal residual disease) reimbursement on the horizon and upcoming regulatory submissions for their liquid biopsy product, xF. Tempus’s data licensing segment showed a 38% growth, marking a successful quarter with $150 million in new contractual value.